Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Atea Pharmaceuticals, Inc./ 10-Q

Quarterly Report · 10-Q

Atea Pharmaceuticals, Inc.

AVIRNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 12, 2026Accepted Aug 12, 2026, 4:45 PM EDTCIK 1593899Accession 0001193125-26-347021
View company →Permanent SEC source ↗
Share

Company context

Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat ssRNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the FDC regimen of BEM, a nucleotide analog polymerase inhibitor, and RZR, an NS5A inhibitor, to treat HCV. AT-587, a nucleotide analog, is in Phase 1 development for the treatment of HEV. For more information, please visit www.ateapharma.com.

Current securities

AVIRNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding Atea Pharmaceuticals, Inc.Oct 6, 2026
  2. Results of Operations and Financial ConditionAug 12, 2026
  3. 4 filingJun 23, 2026
  4. 4 filingJun 23, 2026
  5. 4 filingJun 23, 2026

Registered securities in this filing

Atea Pharmaceuticals, Inc. · 10-Q · Filed 2026-08-12

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.001 par value per share

Symbol
AVIR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_1e670f8e-fd44-4176-8fa7-fa8b7a92652c

Dimensions: Not supplied

Accession 000119312526347021 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.